{"id":573216,"date":"2025-12-26T00:00:00","date_gmt":"2025-12-26T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0001-2025-biopharma-asthma-disease-landscape-and-forecast-g7-2025\/"},"modified":"2026-03-31T10:23:37","modified_gmt":"2026-03-31T10:23:37","slug":"dlsfim0001-2025-biopharma-asthma-disease-landscape-and-forecast-g7-2025","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0001-2025-biopharma-asthma-disease-landscape-and-forecast-g7-2025\/","title":{"rendered":"Asthma | Disease Landscape and Forecast | G7 | 2025"},"content":{"rendered":"<p>The asthma therapy market consists of many well-established drugs, including inhaled agents (e.g., GlaxoSmithKline\u2019s Advair \/ Seretide, AstraZeneca\u2019s Symbicort, Boehringer Ingelheim\u2019s Spiriva, Novartis\u2019s Enerzair); oral drugs (e.g., montelukast); and biologics (e.g., GlaxoSmithKline\u2019s Nucala, Sanofi \/ Regeneron\u2019s Dupixent). The impending approval and launch of additional biological therapies, branded generic and generic inhaled drugs, and LABA\/LAMA\/ICS combination agents for asthma will further increase the competition in this already crowded market.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What insights do thought leaders have on current inhaled branded, branded generic, and generic treatment options? What is the current and future market impact of branded generic and generic inhaled therapies?<\/li>\n<li>What are key opinion leaders\u2019 perceptions of currently marketed asthma biologics (Nucala, Dupixent, Roche \/ Novartis\u2019s Xolair, Teva\u2019s Cinqair \/ Cinqaero, AstraZeneca\u2019s Fasenra, AstraZeneca \/ Amgen\u2019s Tezspire)? What drives physicians\u2019 choice of a biologic for severe refractory asthma? How receptive are physicians to emerging agents, including GlaxoSmithKline\u2019s depemokimab?<\/li>\n<li>How will the market evolve over the next 10 years given the launch of additional inhaled, oral, and biological products? What effect will the uptake of triple LABA\/LAMA\/ICS combination agents have on the sales and patient share of other inhaled therapies?<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States, France, Germany, Italy, Spain, United Kingdom, and Japan.<\/p>\n<p><strong>Primary research:<\/strong> ~20 country-specific interviews with thought leaders.<\/p>\n<p><strong>Epidemiology:<\/strong> Number of diagnosed and drug-treated prevalent cases of asthma; number of diagnosed and drug-treated prevalent cases of intermittent \/ mild persistent and moderate \/ severe persistent asthma.<\/p>\n<p><strong>Drug treatments: <\/strong>Coverage of key current and emerging therapies<\/p>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul>\n<li>Optimize your long-term disease and development strategy.<\/li>\n<\/ul>\n<ul>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<\/ul>\n<ul>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<\/ul>\n<ul>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-573216","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-asthma","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/573216","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/573216\/revisions"}],"predecessor-version":[{"id":575223,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/573216\/revisions\/575223"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=573216"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}